Clindamycin: Potent Antibiotic Therapy for Serious Bacterial Infections

Clindamycin

Product dosage: 150mg
Package (num)	Per pill	Price	Buy
30	$1.44	$43.17 (0%)	🛒 Add to cart
60	$1.22	$86.35 $73.29 (15%)	🛒 Add to cart
90	$1.17	$129.52 $105.42 (19%)	🛒 Add to cart
120	$1.14	$172.69 $136.55 (21%)	🛒 Add to cart
180	$1.09	$259.04 $196.79 (24%)	🛒 Add to cart
270	$1.07 Best per pill	$388.56 $290.17 (25%)	🛒 Add to cart

Product dosage: 300mg
Package (num)	Per pill	Price	Buy
30	$1.61	$48.19 (0%)	🛒 Add to cart
60	$1.39	$96.39 $83.33 (14%)	🛒 Add to cart
90	$1.32	$144.58 $118.48 (18%)	🛒 Add to cart
120	$1.27	$192.77 $152.61 (21%)	🛒 Add to cart
180	$1.24	$289.16 $223.90 (23%)	🛒 Add to cart
270	$1.21 Best per pill	$433.74 $327.32 (25%)	🛒 Add to cart
Synonyms Cleocin pediatric Cleocin phosphate Cleocin hcl

Show more

Clindamycin is a lincosamide antibiotic prescribed for the treatment of a wide range of serious anaerobic and aerobic gram-positive bacterial infections. Its mechanism of action involves inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit, effectively halting bacterial growth and proliferation. This medication is particularly valued in clinical settings for its efficacy against organisms resistant to other antibiotics and its excellent tissue penetration, including bone. Available in oral, topical, and intravenous formulations, clindamycin is a cornerstone in managing skin and soft tissue infections, intra-abdominal infections, and certain respiratory tract infections, providing clinicians with a reliable therapeutic option when penicillin-class agents are unsuitable or ineffective.

Features

• Chemical Classification: Lincosamide antibiotic
• Available Forms: Oral capsules (150 mg, 300 mg), topical solutions/gels/creams (1%), vaginal creams/ovules (2%), intravenous injection (150 mg/mL)
• Mechanism of Action: Binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis
• Spectrum of Activity: Effective against aerobic gram-positive cocci (including some penicillin-resistant staphylococci) and anaerobic bacteria
• Bioavailability: Approximately 90% for oral administration
• Half-life: 2–3 hours in adults with normal renal function
• Metabolism: Hepatic, with both active and inactive metabolites
• Excretion: Primarily via bile and feces; minimal renal excretion

Benefits

• Provides effective treatment for polymicrobial infections involving both aerobic and anaerobic pathogens
• Demonstrates excellent penetration into bone, abscesses, and other poorly vascularized tissues
• Offers flexibility with multiple administration routes (oral, IV, topical) to suit various clinical scenarios
• Serves as an alternative for patients with penicillin allergies when appropriate
• Effective against certain community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) strains
• Helps prevent surgical site infections in specific procedures, particularly colorectal surgery

Common use

Clindamycin is commonly prescribed for bacterial infections caused by susceptible organisms, including:

• Skin and soft tissue infections (abscesses, cellulitis, wound infections)
• Respiratory tract infections (pneumonia, lung abscesses, empyema)
• Intra-abdominal infections (peritonitis, intra-abdominal abscesses)
• Gynecological infections (pelvic inflammatory disease, endometritis)
• Bone and joint infections (osteomyelitis, septic arthritis)
• Dental infections (periodontal abscesses, pericoronitis)
• Toxoplasmosis treatment and prophylaxis (in combination with other agents)
• Malaria treatment (in combination with quinine for chloroquine-resistant areas)
• Bacterial vaginosis (topical formulations)
• Acne vulgaris (topical formulations for inflammatory lesions)

Dosage and direction

Adult Dosage:

• Oral: 150–450 mg every 6–8 hours for serious infections; maximum 1.8 g/day
• IV: 600–2,700 mg/day divided into 2–4 doses; severe infections may require up to 4.8 g/day
• Topical: Apply thin film to affected area twice daily
• Vaginal: One applicatorful (5 g) intravaginally at bedtime for 7 days

Pediatric Dosage:

• Oral: 8–25 mg/kg/day divided into 3–4 doses
• IV: 20–40 mg/kg/day divided into 3–4 doses

Administration Guidelines:

• Take oral capsules with a full glass of water to minimize esophageal irritation
• IV administration should be diluted and infused over at least 10–60 minutes depending on dose
• Complete the full prescribed course even if symptoms improve
• Dosage adjustments required for patients with severe hepatic impairment
• Not recommended for meningitis due to poor cerebrospinal fluid penetration

Precautions

• Clindamycin use has been associated with Clostridioides difficile-associated diarrhea (CDAD), which may range from mild diarrhea to fatal colitis
• Monitor patients for signs of superinfection or fungal overgrowth during prolonged therapy
• Use with caution in patients with gastrointestinal diseases, particularly colitis
• Periodic liver function tests recommended during extended therapy
• May cause skin reactions ranging from mild erythema to severe reactions like Stevens-Johnson syndrome
• Topical applications may cause contact dermatitis; avoid eyes and mucous membranes
• Vaginal formulations may weaken latex condoms and diaphragms
• Elderly patients may be more susceptible to CDAD and require closer monitoring

Contraindications

• Hypersensitivity to clindamycin, lincomycin, or any component of the formulation
• History of antibiotic-associated colitis, including C. difficile infection
• Concomitant use with erythromycin due to potential antagonism
• Severe hepatic impairment without appropriate dosage adjustment
• Premature infants (due to immature metabolic pathways)
• History of regional enteritis or ulcerative colitis

Possible side effect

Common (≥1%):

• Gastrointestinal: Nausea, vomiting, abdominal pain, diarrhea
• Dermatological: Skin rash, itching, erythema
• Local reactions: Pain at injection site, phlebitis (IV administration)
• Topical: Dryness, peeling, burning sensation, oiliness

Less Common (<1%):

• C. difficile-associated diarrhea (may occur during or weeks after therapy)
• Esophagitis, esophageal ulceration (oral administration)
• Transient elevations in liver enzymes
• Neutropenia, eosinophilia, thrombocytopenia
• Metallic taste, jaundice
• Vaginal itching or discharge (with vaginal formulations)
• Anaphylactoid reactions, angioedema

Rare:

• Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis
• Blood dyscrasias: Agranulocytosis, aplastic anemia
• Hepatitis, renal dysfunction
• Neuromuscular blockade (particularly with concurrent use of neuromuscular blocking agents)
• Cardiorespiratory arrest following rapid IV administration

Drug interaction

• Neuromuscular blocking agents: Enhanced neuromuscular blockade effect
• Erythromycin: Potential antagonism; avoid concomitant use
• Kaolin-pectin: Decreased clindamycin absorption; separate administration by at least 2 hours
• Oral contraceptives: Possible reduced efficacy; recommend alternative contraception during therapy
• CYP3A4 inducers (rifampin, phenytoin): May decrease clindamycin levels
• Warfarin: Potential enhanced anticoagulant effect; monitor INR closely
• Cyclosporine: Possible increased cyclosporine levels
• Opioid analgesics: May delay clindamycin absorption

Missed dose

• Take the missed dose as soon as remembered, unless it is almost time for the next scheduled dose
• Do not double the dose to make up for a missed one
• Maintain regular dosing intervals to ensure consistent antibiotic levels
• If multiple doses are missed, contact healthcare provider for guidance
• For topical formulations, apply when remembered and resume regular schedule

Overdose

Symptoms: Severe gastrointestinal distress (nausea, vomiting, diarrhea), neuromuscular blockade, hypotension Management:

• Discontinue clindamycin immediately
• Provide supportive care: fluid replacement, electrolyte management
• Activated charcoal may be beneficial if administered shortly after ingestion
• Hemodialysis is not effective due to high protein binding
• Monitor for signs of C. difficile colitis, which may develop following overdose
• Symptomatic treatment for any specific manifestations
• Contact poison control center for latest management recommendations

Storage

• Store at room temperature (20–25°C or 68–77°F)
• Protect from light and excessive moisture
• Keep oral capsules in tightly closed container
• IV solutions should be stored according to manufacturer’s instructions; typically stable for 24 hours at room temperature after reconstitution
• Keep all medications out of reach of children and pets
• Do not use beyond expiration date printed on packaging
• Do not freeze liquid formulations
• Topical products should not be stored in bathroom due to humidity fluctuations

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Clindamycin is a prescription medication that should only be used under the supervision of a qualified healthcare professional. The prescribing physician will determine the appropriate dosage and duration based on the specific infection, patient factors, and local resistance patterns. Patients should not self-medicate with clindamycin or share their prescription with others. Always report any adverse effects to your healthcare provider promptly. This information may not include all possible uses, directions, precautions, or interactions.

Reviews

“Clindamycin has been invaluable in our surgical practice for preventing post-operative infections in high-risk colorectal procedures. Its anaerobic coverage is particularly effective, though we remain vigilant for C. difficile complications.” — Surgical Department, University Medical Center

“As an infectious disease specialist, I find clindamycin remains relevant despite newer antibiotics. Its bone penetration makes it essential for osteomyelitis treatment, and it’s often our go-to for penicillin-allergic patients with serious staphylococcal infections.” — Director, Infectious Disease Program

“In dermatology, topical clindamycin continues to be a mainstay for inflammatory acne, particularly when combined with benzoyl peroxide to reduce resistance development. Patients appreciate the formulation options available.” — Dermatology Practice

“Our microbiology lab notes consistent susceptibility patterns for clindamycin against many anaerobic isolates, though we’ve observed increasing macrolide-lincosamide-streptogramin B (MLSB) resistance among some staphylococcal strains, necessitating D-testing for inducible resistance.” — Clinical Microbiology Laboratory

“While effective, the association with C. difficile infection requires careful patient selection and monitoring. We’ve implemented stewardship protocols to limit unnecessary use, particularly in elderly patients.” — Hospital Pharmacy and Therapeutics Committee